Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ALX Oncology Holdings Inc.    ALXO

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ALX Oncology : Merck to Collaborate on Head and Neck Cancer Treatment Trials

share with twitter share with LinkedIn share with facebook
09/22/2020 | 08:51am EDT

By Chris Wack

 

ALX Oncology Holdings Inc. said Tuesday it is collaborating with Merck & Co. to evaluate the combination of ALX148 and Keytruda for treating patients with a certain type of head and neck cancer.

Under the terms of the agreement, ALX Oncology will conduct two Phase 2 studies. The first will evaluate the efficacy of ALX148, an investigational next generation CD47 blocker, in combination with Merck's drug to treat patients with PD-L1 expressing metastatic or unresectable, recurrent head and neck squamous cell carcinoma.

The second study will evaluate ALX148, Keytruda and standard chemotherapy to treat patients with metastatic or unresectable, recurrent HNSCC.

ALX Oncology owns worldwide commercial rights to ALX148.

 

Write to Chris Wack at chris.wack@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
ALX ONCOLOGY HOLDINGS INC. -1.05% 39.51 Delayed Quote.0.00%
MERCK & CO., INC. -0.90% 75.21 Delayed Quote.-16.56%
share with twitter share with LinkedIn share with facebook
All news about ALX ONCOLOGY HOLDINGS INC.
10/28ALX ONCOLOGY : Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of A..
AQ
10/28ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ..
GL
10/14ALX ONCOLOGY : to Present ALX148 Clinical Data at the Society for Immunotherapy ..
AQ
10/14ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy..
GL
10/06ALX ONCOLOGY : Names Leading Oncology Experts to Scientific Advisory Board
AQ
10/06ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
GL
09/22ALX ONCOLOGY : Merck to Collaborate on Head and Neck Cancer Treatment Trials
DJ
09/22ALX ONCOLOGY : to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Eval..
AQ
09/22ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Eva..
GL
09/17ALX ONCOLOGY : Added to Russell 2000ģ and 3000ģ Indexes
AQ
More news
Financials (USD)
Sales 2020 1,35 M - -
Net income 2020 -47,3 M - -
Net cash 2020 238 M - -
P/E ratio 2020 -23,4x
Yield 2020 -
Capitalization 1 476 M 1 476 M -
EV / Sales 2020 920x
EV / Sales 2021 1 713x
Nbr of Employees 19
Free-Float 58,1%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 56,40 $
Last Close Price 39,93 $
Spread / Highest target 60,3%
Spread / Average Target 41,2%
Spread / Lowest Target 25,2%
EPS Revisions
Managers
NameTitle
Jaume Pons President, Chief Executive Officer & Director
Corey S. Goodman Executive Chairman
Michael Chang Vice President-Operations
Peter S. GarcŪa Chief Financial Officer
Sophia Randolph Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALX ONCOLOGY HOLDINGS INC.0.00%1 476
GILEAD SCIENCES, INC.-9.93%73 380
REGENERON PHARMACEUTICALS48.02%58 486
VERTEX PHARMACEUTICALS-5.45%53 919
WUXI APPTEC CO., LTD.71.31%40 739
BEIGENE, LTD.80.68%27 143